You are here

earnings

Here's How Moderna Turned a Profit in Q1 Despite Its Sales Declining by 69%

Here's How Moderna Turned a Profit in Q1 Despite Its Sales Declining by 69%

Motley Fool

Moderna Therapeutics

Flag link:

Amylyx’s ALS drug Relyvrio generates $71.4M in Q1

Amylyx’s ALS drug Relyvrio generates $71.4M in Q1

Medical Marketing and Media

Amylyx Pharmaceuticals

Flag link:

Takeda cuts 2 midstage GI assets including Crohn's hopeful in latest pipeline cleanup

Takeda cuts 2 midstage GI assets including Crohn's hopeful in latest pipeline cleanup

Fierce Biotech

Crohn’s disease

Flag link:

Why Shares of MannKind Were Up Wednesday

Why Shares of MannKind Were Up Wednesday

Motley Fool

United Therapeutics

Flag link:

Catalent Delays Earnings Call, Shaves $400M Off FY23 Guidance

Catalent Delays Earnings Call, Shaves $400M Off FY23 Guidance

BioSpace

Flag link:

Cash-rich BioNTech broadens scope as COVID shot sales slide

Cash-rich BioNTech broadens scope as COVID shot sales slide

Yahoo/Reuters

Flag link:

Biogen, Novartis, Sanofi Cull Candidates in Q1 Pipeline Reprioritizations

Biogen, Novartis, Sanofi Cull Candidates in Q1 Pipeline Reprioritizations

BioSpace

Flag link:

Novo Nordisk Q1 Earnings In Line, Sales Miss, View Up

Novo Nordisk Q1 Earnings In Line, Sales Miss, View Up

Yahoo/Zacks.com

Flag link:

Revenues down for Moderna, up for Regeneron in Q1

Revenues down for Moderna, up for Regeneron in Q1

Medical Marketing and Media

Moderna Therapeutics

Flag link:

As Amgen's revenues slide, so too do sales at its big buyout target Horizon

As Amgen's revenues slide, so too do sales at its big buyout target Horizon

Fierce Pharma

Horizon Therapeutics

Flag link:

Zimmer Biomet reports top- and bottom-line growth as orthopedic procedures return

Zimmer Biomet reports top- and bottom-line growth as orthopedic procedures return

Medtech Dive

Flag link:

Pfizer reports strong Q1 earnings, including $18.3B in revenues

Pfizer reports strong Q1 earnings, including $18.3B in revenues

Medical Marketing and Media

Flag link:

Analyst ‘blown away’ by robot-fueled growth of Stryker’s hip and knee sales

Analyst ‘blown away’ by robot-fueled growth of Stryker’s hip and knee sales

Medtech Dive

Flag link:

Amgen cuts lupus programs for futility, hours after Lilly officially walks away from one too

Amgen cuts lupus programs for futility, hours after Lilly officially walks away from one too

Fierce Biotech

Flag link:

Merck beats first-quarter expectations on Keytruda, Gardasil strength

Merck beats first-quarter expectations on Keytruda, Gardasil strength

Reuters

Flag link:

Q1 revenues slide for Amgen, Gilead

Q1 revenues slide for Amgen, Gilead

Medical Marketing and Media

Gilead Sciences

Flag link:

Sanofi, after $8B outlay, sees M&A strategy deliver 2 more duds

Sanofi, after $8B outlay, sees M&A strategy deliver 2 more duds

Fierce Biotech

Principia Biopharma

Flag link:

Roche’s new eye drug pressures Eylea with strong launch

Roche’s new eye drug pressures Eylea with strong launch

BioPharma Dive

Flag link:

Novartis Culls 10% of Pipeline, Doubles Down on Five Core Therapeutic Areas

Novartis Culls 10% of Pipeline, Doubles Down on Five Core Therapeutic Areas

BioSpace

cardiovascular disease

Flag link:

Roche, seeing MAGE magic wane, makes pair of solid tumor bispecifics disappear

Roche, seeing MAGE magic wane, makes pair of solid tumor bispecifics disappear

Fierce Biotech

Flag link:

Pages